Clear opinion differences between Sanofi vs LG over ‘Zemiglo’

Published: 2016-07-15 15:58:24

Updated: 2016-07-15 15:58:24

The outline of the lawsuit over ‘Zemiglo,’ an antidiabetic developed by LG Life Sciences, became visible.

The first defense for the damage suit filed by the previous seller of Zemiglo, Sanofi-Aventis Korea, against the original developer, LG Life Sciences, and the current seller, Daewoong Pharmaceutical, was conducted at the Seoul Central District Court in the morning of the 13^th.

Zemiglo(g...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.